Accepted_test

Structure-guided identification of Baicalin exhibiting anti-Alzheimer’s effects via CLK1 inhibition

Authors:
Sumaiya Khan, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India
Md Imtaiyaz Hassan, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India
Asimul Islam, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India

Abstract ID: 724

Event: BGRS-abstracts

Sections: [Sym 3] Section “Pharmacology cheminformatics and chemical biology”

This study explores the structure-guided binding potential of Baicalin as an inhibitor of CLK1, a kinase implicated in the phosphorylation of tau protein, a hallmark of Alzheimer’s disease (AD). Using molecular docking, molecular dynamics simulations, and fluorescence spectroscopy, Baicalin was found to bind effectively to CLK1. A kinase inhibition assay revealed that Baicalin significantly inhibits CLK1 with an IC50 value of 12.04 μM. These results suggest that Baicalin could serve as a promising lead compound for developing CLK1 inhibitors, offering a new therapeutic strategy for AD and other tau-related disorders.